HLA-A and melanoma: Most notably, vaccination with the gp100-209:217(210M), an HLA-A*0201-restricted epitope derived from the melanoma antigen gp100, significantly improved the clinical response and median overall survival of stage IV melanoma patients receiving IL-2 therapy [2].